Kura Oncology Stock Performance
| KURA Stock | USD 8.31 0.29 3.62% |
The company secures a Beta (Market Risk) of 0.99, which conveys possible diversification benefits within a given portfolio. Kura Oncology returns are very sensitive to returns on the market. As the market goes up or down, Kura Oncology is expected to follow. At this point, Kura Oncology has a negative expected return of -0.36%. Please make sure to verify Kura Oncology's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Kura Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kura Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 3.62 | Five Day Return 7.09 | Year To Date Return (19.63) | Ten Year Return 131.48 | All Time Return (44.60) |
1 | Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades | 11/21/2025 |
2 | Hsbc Holdings PLC Has 784,000 Stake in Kura Oncology, Inc. KURA | 12/11/2025 |
3 | Disposition of 35000 shares by Francis Burrows of Kura Oncology at 4.8 subject to Rule 16b-3 | 12/18/2025 |
4 | Kura Oncology Stock Biotech Battleground With High Hopes And Higher Volatility - AD HOC NEWS | 12/31/2025 |
5 | Acquisition by Bair Teresa Brophy of 100000 shares of Kura Oncology at 10.335 subject to Rule 16b-3 | 01/02/2026 |
6 | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/05/2026 |
7 | Acquisition by Wilson Troy Edward of 13494 shares of Kura Oncology at 6.6417 subject to Rule 16b-3 | 01/07/2026 |
8 | HC Wainwright Reiterates Buy Rating for Kura Oncology | 01/13/2026 |
9 | Disposition of 4777 shares by Bair Teresa Brophy of Kura Oncology at 8.4607 subject to Rule 16b-3 | 01/27/2026 |
10 | Kura Oncology COO Kathleen Ford Sells 1,813 Shares of Stock | 01/28/2026 |
11 | Dont Ignore The Insider Selling In Kura Oncology - simplywall.st | 01/29/2026 |
12 | 1 Under-10 Stock Set to Surge as Much as 850 percent in 2026 | 02/12/2026 |
| Begin Period Cash Flow | 37.3 M | |
| Total Cashflows From Investing Activities | -101.6 M |
Kura Oncology Relative Risk vs. Return Landscape
If you would invest 1,085 in Kura Oncology on November 17, 2025 and sell it today you would lose (254.00) from holding Kura Oncology or give up 23.41% of portfolio value over 90 days. Kura Oncology is currently does not generate positive expected returns and assumes 3.8635% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Kura, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kura Oncology Target Price Odds to finish over Current Price
The tendency of Kura Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.31 | 90 days | 8.31 | about 88.38 |
Based on a normal probability distribution, the odds of Kura Oncology to move above the current price in 90 days from now is about 88.38 (This Kura Oncology probability density function shows the probability of Kura Stock to fall within a particular range of prices over 90 days) .
Kura Oncology Price Density |
| Price |
Predictive Modules for Kura Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kura Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Kura Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Kura Oncology is not an exception. The market had few large corrections towards the Kura Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kura Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kura Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 0.99 | |
σ | Overall volatility | 1.34 | |
Ir | Information ratio | -0.08 |
Kura Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kura Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kura Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 53.88 M. Net Loss for the year was (173.98 M) with loss before overhead, payroll, taxes, and interest of (120.28 M). | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 1 Under-10 Stock Set to Surge as Much as 850 percent in 2026 |
Kura Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kura Stock often depends not only on the future outlook of the current and potential Kura Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kura Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 86.2 M | |
| Cash And Short Term Investments | 727.4 M |
Kura Oncology Fundamentals Growth
Kura Stock prices reflect investors' perceptions of the future prospects and financial health of Kura Oncology, and Kura Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kura Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (2.08) % | ||||
| Operating Margin | (3.86) % | ||||
| Current Valuation | 193.79 M | ||||
| Shares Outstanding | 87.02 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 2.98 X | ||||
| Price To Sales | 6.95 X | ||||
| Revenue | 53.88 M | ||||
| Gross Profit | (120.28 M) | ||||
| EBITDA | (169.5 M) | ||||
| Net Income | (173.98 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 16.59 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | 134.32 M | ||||
| Earnings Per Share | (2.48) X | ||||
| Market Capitalization | 723.12 M | ||||
| Total Asset | 760.16 M | ||||
| Retained Earnings | (895.42 M) | ||||
| Working Capital | 666.12 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
About Kura Oncology Performance
By analyzing Kura Oncology's fundamental ratios, stakeholders can gain valuable insights into Kura Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kura Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kura Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.33) | (0.31) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about Kura Oncology performance evaluation
Checking the ongoing alerts about Kura Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kura Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kura Oncology generated a negative expected return over the last 90 days | |
| Kura Oncology has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 53.88 M. Net Loss for the year was (173.98 M) with loss before overhead, payroll, taxes, and interest of (120.28 M). | |
| Kura Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: 1 Under-10 Stock Set to Surge as Much as 850 percent in 2026 |
- Analyzing Kura Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kura Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Kura Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kura Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kura Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kura Oncology's stock. These opinions can provide insight into Kura Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |